triglycerides were 275 mg/dl (3-1 mmol/l) (normal 50-175 (0-56-1 98 mmol/l)) and erythrocyte sedimentation rate (ESR) by the Westergren method was 13 mm/h. A diagnosis of nonarteritic ischaemic optic neuropathy was made. No treatment was instituted.
His vision remained unchanged for 3 weeks, when he experienced a second episode of sudden visual loss in his right eye, this time in the superior field. Acuity was 6/240 OD with only an island of visual field remaining in the superior nasal quadrant. The superior portion of the right disc was now pale, but most of the swelling had resolved, and dilated vessels were no longer present on its surface. The inferior portion of the disc, which had previously been normal, now had pallid oedema with haemorrhages in the adjacent nerve fibre layer (Fig. lb) . A repeat ESR was 10 mm/h. No therapy was instituted. CASE 
2
A 59-year-old man reported the sudden loss of vision in the inferior visual field of his right eye. He was otherwise well and his medical history was not remarkable. Visual acuity was 6/9 OD and 6/6 OS. An afferent pupillary defect and an inferior altitudinal visual field loss were found in the right eye. The right disc was pale and oedematous superiorly (Fig. 2a) ; the left disc and field were unremarkable. The intraocular tension, serum glucose, and ESR (21 mm/h) were normal. Systemic blood pressure was 190/110 mmHg. A diagnosis of nonarteritic ischaemic optic neuropathy was made. Antihypertensive treatment 705 A differentiation must be made between progression of a visual field deficit within a single episode of AION and a distinctly separate second episode. Boghen and Glaser3 found visual loss to be progressive to some degree in 11 out of 39 eyes. In most of the patients progression occurred over a period of one to 9 days. Ellenberger et al.7 had no patients in whom visual loss progressed over more than one day. Cullen6 found no evidence of progression in any of 19 patients with 'arteriosclerotic' AION. Miller and Smith' described progression of visual loss in one of 11 patients with AION. This patient's visual acuity decreased from 6/9 at the initial examination to 6/21. The time course of the reduction in acuity and its aetiology were not discussed. Shults'6 reported on a 39-year-old male who developed bilateral consecutive AION in whom visual loss progressed over about one week in each eye.
All 4 of our patients had a definite, documented second episode of AION. The interval between the 2 episodes in the first 3 cases was 3, 3, and 1 week respectively. Despite these relatively short intervals of time the 2 episodes in each patient were distinctly separate. In each case there was an initial sudden loss of inferior visual field which corresponded to an observed oedema of the superior portion of the disc. This field defect remained stable but was followed by a second apoplectic episode of visual loss involving the superior visual field. The inferior portion of the disc, which was initially normal, became oedematous with haemorrhages at the margin, while most of the oedema of the superior portion of the disc had resolved.
In patient 4 almost 4 years elapsed between the 2 episodes of AION. In both episodes there was diffuse disc oedema with haemorrhages in the adjacent nerve fibre layer and involvement of the inferior visual field.
Our 4 patients differ in no way from the accepted clinical profile of AION. Their age range was 48 to 61 and all were in good health, without systemic evidence of significant atherosclerotic disease. The ESR was normal in each patient during each episode, and none had systemic symptoms or signs of giant cell arteritis. Two of the patients (2 and 4) had mild hypertension, one (3) had mild hypertriglyceridaemia, and one (1) had borderline untreated diabetes mellitus and mild hypertriglyceridaemia. In no patient was there evidence of any other systemic disease or embolic phenomena which may have contributed to optic nerve infarction. Two patients (3 and 4) were admitted to hospital and thoroughly examined for a systemic cause of repeated episodes of optic neuropathy, but none was found. Although there was no evidence of giant cell arteritis, two patients (2 and 4) received systemic corticosteroids, but neither had improvement in vision.
Why repeated episodes of AION in the same eye should occur so infrequently is not known. One possible explanation is that, having suffered one episode of AION, a patient might be less likely to recognise further visual loss in the same eye, and thus the calculated incidence of recurrent AION in the same eye might be falsely lowered. As evidence against this we detected additional asymptomatic visual field loss in only one of 58 patients with AION whom we have followed up with sequential perimetry for at least 3 years (unpublished data). It is more likely that certain unknown constant features of the structure of the optic nerve head or its blood supply provide the explanation. It is possible that when a portion of the optic disc is infarcted the blood supply which is subsequently shunted away from this area is sufficient to protect the remainder of the disc from a second ischaemic episode.
Two independent episodes of AION may occur in the same eye. Although rare, it does not appear to reflect any underlying systemic abnormality other than those noted in patients with AION in general.
